Arkolith/Insider Trading/AVIR/Form 4

Sommadossi Jean-Pierre

President, CEO, and Chairman, DirectorAtea Pharmaceuticals, Inc. (AVIR) · full profile →Form 4 · filed Feb 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2026Option exercise(M)300K$1.24$372K768K
Jan 31, 2026Tax withholding(F)106K$4.24$450K468K
Jan 31, 2026Option exercise(M)273K——574K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2026Option exercise(M)300K—$00
Jan 31, 2026Option exercise(M)173K—$00
Jan 31, 2026Option exercise(M)100K—$00

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-036268) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML